CS
TCRR

Candriam SCA’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Candriam SCA’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-934,551
Closed -$15.3M – 923
2021
Q2 		$15.3M Buy
934,551
+540,263
+137% +$10.9M 0.11% 226
2021
Q1 		$11.7M Buy
394,288
+6
+0% +$164 0.1% 227
2020
Q4 		$12.2M Buy
+394,282
New +$9.97M 0.1% 231

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Candriam SCA's TCRR Position: Q3 2021 in Review

Candriam SCA sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2021, closing a stake of 934,551 shares — an estimated $15.3M sold.

Candriam SCA first reported a position in TCRR in Q4 2020 and held it in 3 quarters. The position peaked at $15.3M in Q2 2021. 117 funds tracked by Wall St. Rank hold TCRR as of Q3 2021.

  • Candriam SCA reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Candriam SCA sold 934,551 TCR2 Therapeutics Inc. Common Stock shares in Q3 2021, an estimated $15.3M.
  • Candriam SCA first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Candriam SCA's TCR2 Therapeutics Inc. Common Stock position peaked at $15.3M in Q2 2021.
  • 117 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2021.

Based on Candriam SCA's 13F filing for Q3 2021, filed 9 Nov 2021.